Ontology highlight
ABSTRACT:
SUBMITTER: Pharaon R
PROVIDER: S-EPMC7578474 | biostudies-literature | 2020 Sep
REPOSITORIES: biostudies-literature
Pharaon Rebecca R Koczywas Maria A MA Salgia Sabrina S Mohanty Atish A Massarelli Erminia E
Journal of thoracic disease 20200901 9
Within the past decade, immunotherapy has revolutionized the treatment of advanced non-small lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) such as pembrolizumab, nivolumab, atezolizumab, and durvalumab have shown superiority over chemotherapy regimens in patients with programmed death-ligand 1 (PD-L1) expression. Several predictive molecular biomarkers, including PD-L1 expression and high tumor mutation burden, have shown utility in discovering lung cancer patient groups that would be ...[more]